DOCSLIB.ORG

Synergistic in Vitro Activity of MOR209/ES414 in Combination

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Synergistic in Vitro Activity of MOR209/ES414 in Combination AACR Annual Meeting 16-20 April 2016 - Poster #280 Synergistic in vitro activity of MOR209/ES414 in combination with enzalutamide 1Emergent Product Development Seattle – Seattle, WA, USA Toddy Sewell1, Jan Endell2, Johannes Weirather2, Michelle Blake1, Jane Gross1, and John W. Blankenship1 and 2MorphoSys AG – Martinsried/Planegg, Germany Combination Treatment of LNCaP Cells with Introduction Enzalutamide Drug Activity on LNCaP Cells Monitored by Fluorescence MOR209/ES414 and Enzalutamide Metastatic castrate-resistant prostate cancer (mCRPC) presents a daunting therapeutic Enzalutamide (previously known as MDV3100) is a non-steroidal MOR209/ES414 is cytotoxic to CRPC cells by a different mode of action than enzalutamide, Combinations of MOR209/ES414 and enzalutamide were tested in a 96 well plate fluorolysis challenge for patients who eventually progress after androgen ablation therapy. Although newer androgen receptor (AR) inhibitor. It was approved for oral dosing of directing T cells to lyse PSMA-bearing tumor cells. Enzalutamide inhibits the growth of assays using LNCaP(GFP) cells in culture with primary T cells. Surviving LNCaP cells were approaches to antagonize androgen receptor signaling such as enzalutamide or blockading mCRPC patients in 2012. Enzalutamide impairs AR translocation to tumor cells dependent on androgen signaling. To enable measurement of the impacts of the quantitated 4-5 days later. Data shown is from one of four similar experiments, using T cells androgen biosynthesis such as abiraterone provide a survival benefit to patients, patients the nucleus and AR binding to DNA. It is an effective antagonist of two drugs simultaneously, a multi-day growth inhibition assay was needed. At least 4 days from 3 healthy donors. treated with these therapies ultimately relapse. Thus, it is critical to identify new therapies that AR receptor signaling with no agonist activity. of target cell growth were required to provide accurate data on growth inhibition by will work in combination with AR antagonists or in settings where patients have developed enzalutamide. Enzalutamide did not interfere with the ability of MOR209/ES414 to target T cells to LNCaP cells, resistance to hormonal therapies. MOR209/ES414 is a bispecific ADAPTIRTM (modular protein In phase III trials enzalutamide was found to prolong the survival of and augmented the effect of MOR209/ES414 when used at suboptimal concentrations. technology) molecule currently under investigationinaphase1clinicaltrialinmCRPC,including men with mCRPC, reduce the risk of death, significantly improve LNCaP cells provided a PSMA-positive, enzalutamide-sensitive cell line for testing patients that have progressed on enzalutamide or abiraterone. In pre-clinical studies, quality of life measures, and demonstrate consistent safety and MOR209/ES414 in combination with enzalutamide. LNCaP cells transduced to express Green 100 MOR209/ES414 has previously been shown to redirect T-cell cytotoxicity against cells tolerability across all patient subgroups.b,c Fluorescent Protein (GFP) were obtained from AntiCancer, Inc. Fluorescence from GFP 0 nM Enzalutamide - MOR209 a expressing Prostate Specific Membrane Antigen (PSMA). Here, we aimed to determine provided a reliable method to monitor target cell growth in the presence of T-cells 80 39 nM Enzalutamide - MOR209 whether enzalutamide affects PSMA expression on CRPC cells in vitro,andcouldalterthe Despite the improved survival benefitthatenzalutamideprovides, (fluorolysis, or loss of fluorescence from lysed cells). Primary T cells were used as effector patients ultimately relapse. Therapeutic agents which can work in 156 nM Enzalutamide - MOR209 effectiveness of MOR209/ES414 at inducing T-cell mediated tumor cell death. cells. 60 combination with enzalutamide, or in patients who have developed 625 nM Enzalutamide - MOR209 resistance, are critically needed. MOR209/ES414: ADAPTIR Molecule Targeting PSMA and CD3 For fluorolysis assays, LNCaP (GFP+) were cocultured with primary T cells and 40 2500 nM Enzalutamide - MOR209 MOR209/ES414 for 3-5 days in 96 well plates. LNCaP cells are colored green in images, and cells dead % T cells are visible by blue nuclear staining from Hoechst. Images show the cell loss from 20 ADAPTIR molecules are bispecific antibody-like therapeutics 22Rv1 Prostate Cancer Cell Line is Enzalutamide Resistant redirected T cell cytotoxicity when target cells are cultured with T cells and MOR209/ES414. containing two sets of binding domains linked to immunoglobulin Fc 0 domains to extend the half-life of the molecule in vivo. PSMA scFv 0.0 0.5 1.0 1.5 2.0 2.5 To confirm the sensitivity or resistance of several MOR209/ES414 is an ADAPTIR molecule that binds both PSMA and log c MOR209 [pM] prostate cancer cell lines to enzalutamided,e,cells CD3 to redirect T-cell cytotoxicity against PSMA expressing tumor 120 cells. The anti-PSMA binding domain is a humanized single chain weregrownin96wellplatesfor7daysinthe presence of the drug. Cell number was quantitated variable fragment (scFv) derived from a murine antibody that binds effector null Fc 100 Combination Index Analysis human and non-human primate (NHP) PSMA. The anti-CD3 binding by Cell Titer Glo luminescence and expressed as a 22Rv1 ratio to signal from untreated wells. 80 domain is a humanized scFv adapted from a murine antibody that MDA-PCa-2b f binds human and NHP CD3. In order to avoid interactions with other 60 Combination Index analysis following the method of Chou and Talalay was used to determine components of the immune system that could lead to CD3 22Rv1 and MDA-PCa-2b cell lines were shown to be VCaP whether or not the combination of MOR209/ES414 with enzalutamide was additive or enzalutamide-resistant. VCaPandLNCaPcellswere 40 clustering and non-specific T cell activation, the Fc region of CD3 scFv LNCaP synergistic in vitro. When plotted on Fa-CI plots (below), the activity of MOR209/ES414 and sensitive to enzalutamide, with EC50 values of 113 enzalutamide was synergistic in vitro at most concentrations of MOR209/ES414 and MOR209/ES414, has been engineered to minimize complement % of untreated control 20 15.6 pM fixation and interaction with Fc receptors. nM and 298 nM, respectively. Growth of VCaP and untreated MOR209/ES414 enzalutamide. LNCaP cells was inhibited 60-70% over a 7 day 0 treatment period. 0 0.001 0.01 0.1 1 10 M enzalutamide 156 nM enzalutamide 625 nM enzalutamide Redirected T Cell Cytotoxicity (RTCC) by MOR209/ES414 39 nM Enzalutamide Enzalutamide Increases PSMA Expression in 22Rv1 Cells 1.5 1.5 1.5 1.0 1.0 Prostate Specific 22Rv1 cells (ATCC) are androgen-independent, 90 1.0 CI Membrane Antigen AR-positive, and PSMA-positive. Resistance of 3 wk + enza 80 (PSMA) this cell line to enzalutamide provided the 0.5 0.5 0.5 2 wk + enza opportunity to explore whether treatment of this 70 model of mCRPC with enzalutamide would affect 1 wk + enza 0.0 Elimination of 60 0.0 0.0 PSMA expression. MFI no enza 62.5 pM 250 pM tumor cells by Tumor 50 MOR209/ES414 MOR209/ES414 release of Parallel cultures of 22Rv1 cells were treated with cell pM MOR209/ES414 pM MOR209/ES414 pM MOR209/ES414 cytotoxic 10 M enzalutamide for 1-3 weeks, with twice 40 granules weekly passages into fresh media, then stained 30 Single Agent Activity of MOR209/ES414 for PSMA expression using FITC-labeled anti- 0 0.1 1 10 PSMA mAb. nM mAb and Enzalutamide on LNCaP Cells MOR209/ES414: Summary and Conclusions Bispecific An increase in cell surface PSMA expression could 22rv1 22rv1+enza molecule cross- be measured by flow cytometry after 1 week of (no enza) 3 wk MOR209/ES414 and enzalutamide were titrated individually on LNCaP(GFP) cells, using . Treatment with enzalutamide increased PSMA expression on enzalutamide-resistant 22Rv1 links tumor cell enzalutamide treatment, and a further increase in fluorolysis assay conditions designed to accommodate the different mechanisms of action of cells, and also increased the sensitivity of 22Rv1 cells to T-cell mediated lysis induced by and T cell PSMA expression was seen at 2 and 3 weeks. both drugs. LNCaP cells were cultured for 5 days in the presence of a 3:1 ratio of primary T anti-PSMA mAb cells to target cells, necessary for MOR209/ES414, and with 0.2% DMSO present, a MOR209/ES414. unstained T cell necessary control for enzalutamide. Treatment of enzalutamide-sensitive LNCaP cells with suboptimal concentrations of CD3/TCR expansion MOR209/ES414 and enzalutamide showed a synergistic increase in activity as determined by complex The EC50 for MOR209/ES414 was 14.5 pM under these conditions. Enzalutamide affected cell Combination Index analysis. growth with an EC50 of 218 nM. Five days’ culture of LNCaP(GFP) cells with enzalutamide Enzalutamide Increases Susceptibility of 22Rv1 Cells to RTCC inhibited cell growth by 25% at the maximal dose of 10 M, as opposed to 100% inhibition by MOR209/ES414 at the maximal dose of 125 pM. These studies provide a rationale for further examination of combining MOR209/ES414 with enzalutamide, even in enzalutamide-resistant settings. T cell 22Rv1 cells are efficiently lysed by RTCC using Cytotoxic 30 unstimulated primary T cells and MOR209/ES414, 100 granule despite their low level of PSMA expression. A 3 wk + enza 100 25 References chromium-51 release assay was used to examine 2 wk + enza 80 whether exposure to enzalutamide would affect the 20 90 a Sewell, T et al, anti-PSMA x anti-CD3 bispecific antibody redirects T cell cytotoxicity in castrate-resistant prostate sensitivity of 22Rv1 cells to T-cell mediated lysis. 1 wk + enza 60 cancer models. 2012 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Dublin, Ireland. b Scher, H., Fizazi, K., Saad, F., Taplin, M., Sternberg, C., Miller, K. et al. (2012) Increased survival with enzalutamide 15 no enza 22Rv1 cells exposed to enzalutamide were more 80 in prostate cancer after chemotherapy. N Engl J Med 367: 1187–1197. 40 c Beer, T., Armstrong, A., Rathkopf, D., Loriot, Y., Sternberg, C., Higano, C.
Load more

Recommended publications
  • P53 and PTEN Expression Contribute to the Inhibition of EGFR Downstream Signaling Pathway by Cetuximab
    Cancer Gene Therapy (2009) 16, 498–507 r 2009 Nature Publishing Group All rights reserved 0929-1903/09 $32.00 www.nature.com/cgt ORIGINAL ARTICLE P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab S Bouali1, A-S Chre´tien1, C Ramacci1, M Rouyer1, S Marchal2, T Galenne3, P Juin3, P Becuwe4 and J-L Merlin1 1Centre Alexis Vautrin, Unite´ de Biologie des Tumeurs, EA ‘‘Predicther’’ Nancy Universite´, Vandœuvre-le`s- Nancy cedex, France; 2Centre Alexis Vautrin, CRAN UMR 7039 CNRS-UHP-INPL, Vandœuvre-le`s-Nancy cedex, France; 3INSERM U601, CHU de Nantes, Institut de Biologie, Nantes, France and 4Laboratoire de Biologie Cellulaire, Faculte´ des Sciences, EA ‘‘Predicther’’ Nancy Universite´, Vandœuvre-le`s-Nancy, France Cetuximab (Erbitux) is an anti-epidermal growth factor receptor (EGFR) monoclonal antibody whose activity is related to the inhibition of EGFR downstream signaling pathways. P53 and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) have been reported to control the functionality of PI3K/AKT signaling. In this study we evaluated whether reintroducing P53 using non-viral gene transfer enhances PTEN-mediated inhibition of PI3K/AKT signaling by cetuximab in PC3 prostate adenocarcinoma cell line bearing p53 and pten mutations. Signaling phosphoproteins expression was analyzed using Bio-Plex phosphoprotein array and western blot. Apoptosis induction was evaluated from BAX expression, caspase-3 activation and DNA fragmentation analyses. The results presented show that p53 and pten gene transfer additionally mediated cell growth inhibition and apoptosis induction by restoral of signaling functionality, which enabled the control of PI3K/AKT and MAPKinase signaling pathways by cetuximab in PC3 cells.
    [Show full text]
  • Indirect Antitumor Effects of Bisphosphonates on Prostatic Lncap Cells Co-Cultured with Bone Cells
    ANTICANCER RESEARCH 29: 1089-1094 (2009) Indirect Antitumor Effects of Bisphosphonates on Prostatic LNCaP Cells Co-cultured with Bone Cells TOMOAKI TANAKA, HIDENORI KAWASHIMA, KEIKO OHNISHI, KENTARO MATSUMURA, RIKIO YOSHIMURA, MASAHIDE MATSUYAMA, KATSUYUKI KURATSUKURI and TATSUYA NAKATANI Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan Abstract. Bisphosphonates are strong inhibitors of effectively inhibit bone absorption are available for osteoclastic bone resorption in both benign and malignant reducing the risk of skeletal complications in bone bone diseases. The nitrogen-containing bisphosphonates metastases of prostate cancer as well as those of other solid (N-BPs) have strong cytotoxicity via inhibition of protein tumors characterized by osteoclastic lesions. prenylation in the mevalonate pathway, and also demonstrate Bisphosphonates are potent inhibitors of osteoclast activity direct cytostatic and proapoptotic effects on prostate cancer and survival, thereby reducing osteoclast-mediated bone cells. We confirmed the usefulness of a co-culture system absorption (1, 4-6). The chemical structure of bisphosphonates comprised of prostatic LNCaP cells, ST2 cells (mouse- contributes to their mechanism of action: Non-nitrogen- derived osteoblasts) and MLC-6 cells (mouse-derived containing compounds (e.g. etidronate, clodronate) are osteoclasts) in vitro. N-BPs (pamidronate and zoledronic metabolized to cytotoxic analogues of ATP (7), while newer acid) inhibited both androgen receptor transactivation and nitrogen-containing bisphosphonates (N-BPs; pamidronate, tumor cell proliferation by suppressing the activities of both ibandronate, zoledronic acid) have strong cytotoxic effects on osteoclasts and osteoblasts with low-dose exposure. This cells via inhibition of protein prenylation in the mevalonate indirect inhibition of prostate cancer cells via bone cells pathway (8, 9).
    [Show full text]
  • Prostate Cancer Stromal Cells and Lncap Cells Coordinately Activate
    Endocrine-Related Cancer (2009) 16 1139–1155 Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone Atsushi Mizokami, Eitetsu Koh, Kouji Izumi, Kazutaka Narimoto, Masashi Takeda, Seijiro Honma1, Jinlu Dai 2, Evan T Keller 2 and Mikio Namiki Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, 13-1 Takaramachi, Kanazawa City 920-8640, Japan 1Teikoku Hormone MFG. Co., 1604 Shimosakunobe, Takatsu-ku, Kawasaki, Kanagawa 213, Japan 2Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan, USA (Correspondence should be addressed to A Mizokami; Email: [email protected]) Abstract One of the mechanisms through which advanced prostate cancer (PCa) usually relapses after androgen deprivation therapy (ADT) is the adaptation to residual androgens in PCa tissue. It has been observed that androgen biosynthesis in PCa tissue plays an important role in this adaptation. In the present study, we investigated how stromal cells affect adrenal androgen dehydroepian- drosterone (DHEA) metabolism in androgen-sensitive PCa LNCaP cells. DHEA alone had little effect on prostate-specific antigen (PSA) promoter activity and the proliferation of LNCaP cells. However, the addition of prostate stromal cells or PCa-derived stromal cells (PCaSC) increased DHEA-induced PSA promoter activity via androgen receptor activation in the LNCaP cells. Moreover, PCaSC stimulated the proliferation of LNCaP cells under physiological concentrations of DHEA. Biosynthesis of testosterone or dihydrotestosterone from DHEA in stromal cells and LNCaP cells was involved in this stimulation of LNCaP cell proliferation. Androgen biosynthesis from DHEA depended upon the activity of various steroidogenic enzymes present in stromal cells.
    [Show full text]
  • Cell Line Lncap'
    ICANCER RESEARCH58. 76-83. January 1. 1998J Caspase-7 Is Activated during Lovastatin-induced Apoptosis of the Prostate Cancer Cell Line LNCaP' Marco Marcelli,2 Glenn R. Cunningham, S. Joe Haidacher, Sebastian J. Padayatty, Lydia Sturgis, Carolina Kagan, and Larry Denner Departments of Medicine (M. M.. G. R. C., S. J. H.. S. f. P.1 and Cell Biology [M. M., G. R. C.], Veterans Affairs Medical Center and Baylor College of Medicine, Department of Cell Biology (L S., C K., L DI, Texas Biotechnology C'orporation, Houston, Texas 77030 ABSTRACT androgen-dependent and androgen-independent cells even before therapy (4). The initial response following androgen ablation is The goals of this work were to establish a reproducible and effective thought to be due to the induction of apoptosis of androgen-dependent model of apoptosis in a cell line derived from advanced prostate cancer prostate cancer cells (5). Because androgen-independent cells are and to study the role of the caspase family of proteases in mediating insensitive to androgen ablation, they remain alive even in the absence apoptosis in this system. The study involved the use of the prostate cancer cell line LNCaP. Apoptosis was induced using the hydroxymethyl glutaryl of androgens (6). Hence, after the initial response to androgen ablation CoA reductase inhibitor, lovastatin, and was evaluated by agarose gel due to the death of androgen-dependent cells, the tumor progresses to electrophoresis of genomic DNA, morphological criteria, and terminal an androgen-independent state, and the patient is no longer curable deoxynucleotidyl traasferase-mediated nick end labeling. Caspases were (7).
    [Show full text]
  • On the Biological Properties of Prostate Cancer Cells by Modulation of Inflammatory and Steroidogenesis Pathway Genes
    International Journal of Molecular Sciences Article The Impact of Ang-(1-9) and Ang-(3-7) on the Biological Properties of Prostate Cancer Cells by Modulation of Inflammatory and Steroidogenesis Pathway Genes Kamila Domi ´nska 1,* , Karolina Kowalska 2 , Kinga Anna Urbanek 2 , Dominika Ewa Habrowska-Górczy ´nska 2 , Tomasz Och˛edalski 1 and Agnieszka Wanda Piastowska Ciesielska 2 1 Department of Comparative Endocrinology, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Lodz, Poland; [email protected] 2 Department of Cell Cultures and Genomic Analysis, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Lodz, Poland; [email protected] (K.K.); [email protected] (K.A.U.); [email protected] (D.E.H.-G.); [email protected] (A.W.P.C.) * Correspondence: [email protected] Received: 12 July 2020; Accepted: 26 August 2020; Published: 28 August 2020 Abstract: The local renin–angiotensin system (RAS) plays an important role in the pathophysiology of the prostate, including cancer development and progression. The Ang-(1-9) and Ang-(3-7) are the less known active peptides of RAS. This study examines the influence of these two peptide hormones on the metabolic activity, proliferation and migration of prostate cancer cells. Significant changes in MTT dye reduction were observed depending on the type of angiotensin and its concentration as well as time of incubation. Ang-(1-9) did not regulate the 2D cell division of either prostate cancer lines however, it reduced the size of LNCaP colonies formed in soft agar, maybe through down-regulation of the HIF1a gene.
    [Show full text]
  • Active Estrogen Synthesis and Its Function in Prostate Cancer-Derived Stromal Cells
    ANTICANCER RESEARCH 35: 221-228 (2015) Active Estrogen Synthesis and its Function in Prostate Cancer-derived Stromal Cells KAZUAKI MACHIOKA1, ATSUSHI MIZOKAMI1, YURI YAMAGUCHI2, KOUJI IZUMI1, SHINICHI HAYASHI3 and MIKIO NAMIKI1 1Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Ishikawa, Japan; 2Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; 3Department of Molecular and Functional Dynamics, Graduate School of Medicine, Tohoku University, Sendai, Japan Abstract. Background: It remains unclear whether estrogen Castration-naïve prostate cancer (PCa) develops into is produced in prostate cancer (PCa) and how it functions in castration-resistant prostate cancer (CRPC) during androgen PCa. Materials and Methods: To examine the production of deprivation therapy (ADT) by various mechanisms. estrogen in PCa cells, the concentration of estrogen in the Especially, the androgen receptor (AR) signaling axis plays a medium in which LNCaP cells and PCa-derived stromal cells key role in this specific development. PCa cells mainly adapt (PCaSC) were co-cultured, was measured by liquid themselves to the environment of lower androgen chromatography-mass spectrometry/mass spectrometry (LC- concentrations and change into androgen-hypersensitive cells MS/MS), while aromatase (CYP19) mRNA expression was or androgen-independent cells. Androgens of adrenal origin confirmed by real-time polymerase chain reaction (RT-PCR) and their metabolites synthesized in the microenvironment in methods. To verify whether estrogen is synthesized from an intracrine/paracrine fashion act on surviving PCa cells and testosterone in PCaSC functions, PCaSC were co-cultured secrete prostate specific antigen (PSA). Therefore, new with breast cancer MCF-7-E10 cells, which were stably- recently developed medicines, abiraterone acetate that transfected with ERE-GFP, in the presence of testosterone.
    [Show full text]
  • Cell Adhesion and Chemotaxis in Prostate Cancer Metastasis to Bone: a Minireview
    Prostate Cancer and Prostatic Diseases (2000) 3, 6±12 ß 2000 Macmillan Publishers Ltd All rights reserved 1365±7852/00 $15.00 www.nature.com/pcan Review Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview CR Cooper1* & KJ Pienta1 1University of Michigan Comprehensive Cancer Center, Department of Internal Medicine, Ann Arbor, MI 48109, USA Bone metastasis is a common phenomenon in patients with advanced prostate cancer. The molecular and cellular mechanisms involved in this process are not well understood. Past reviews on this subject primarily focused on prostate tumor growth in the bone marrow and the effects this growth has on bone homeostasis (ie osteoblastic and osteolytic). Cell chemotaxis and adhesion are also important for site-speci®c metastasis. In this review we have focused on chemotactic and cell adhesion molecules potentially involved in prostate cancer metastasis to bone. In addition, recently developed animal models for prostate cancer metastasis to bone are discussed. Prostate Cancer and Prostatic Diseases (2000) 3, 6±12. Keywords: cell adhesion molecules; cytokines; human bone marrow endothelial cells; chemoattractants; prostate cancer cells Introduction cells.7 The inactivation of parathyroid hormone-related protein (PTH-rp) by prostate-speci®c antigen may pro- Prostate cancer bone metastasis is a major clinical prob- mote the osteoblastic reaction seen in prostate cancer lem and is commonly associated with intractable pain, patients. Yoneda has proposed that the minor osteolytic pathological
    [Show full text]
  • A Novel Anti-Androgen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth in Vitro and in Vivo
    Author Manuscript Published OnlineFirst on March 14, 2013; DOI: 10.1158/1535-7163.MCT-12-0798 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. A novel anti-androgen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo Hidetoshi Kuruma1, Hiroaki Matsumoto1, Masaki Shiota1, Jennifer Bishop, Francois Lamoureux1, Christian Thomas1, David Briere2, Gerrit Los2, Martin Gleave1, Andrea Fanjul2 and Amina Zoubeidi1 1The Vancouver Prostate Centre, 2660 Oak Street, Vancouver, BC, Canada, V6H 3Z6 2Pfizer Oncology Research Unit, Worldwide Research & Development, 10646 Science Center Drive, San Diego, California, United States, 92121. Running Title: Efficacy of Compound 30 in MDV3100-resistant prostate cancer Key words: Castration-resistant prostate cancer, anti-androgen, MDV3100, Compound 30, androgen receptor, MR49F Financial support: Pfizer Global Research & Development (United States) and the Prostate Cancer Foundation USA (A. Zoubeidi) Corresponding author: Amina Zoubeidi, Ph.D. The Vancouver Prostate Centre, Department of Urologic Science University of British Columbia: 2660 Oak Street, Vancouver, BC, V6H 3Z6, Canada. [email protected] Disclosure: A. Fanjul, D. Briere and G. Los are employee of Pfizer. The other authors disclosed no potential conflicts of interest. Manuscript Type: Chemical (Small Molecule) Discovery and Clinical Development Total number of figures: 5 Word Count: 4,937 1 Downloaded from mct.aacrjournals.org on September 29, 2021. © 2013 American Association for Cancer Research. Author Manuscript Published OnlineFirst on March 14, 2013; DOI: 10.1158/1535-7163.MCT-12-0798 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Repression of Cell Proliferation and Androgen Receptor Activity in Prostate Cancer Cells by 2’-Hydroxyflavanone
    ANTICANCER RESEARCH 33: 4453-4462 (2013) Repression of Cell Proliferation and Androgen Receptor Activity in Prostate Cancer Cells by 2’-Hydroxyflavanone MITSUO OFUDE1, ATSUSHI MIZOKAMI1, MISAKO KUMAKI1, KOUJI IZUMI1, HIROYUKI KONAKA1, YOSHIFUMI KADONO1, YASUHIDE KITAGAWA1, MINKYOUNG SHIN1, JIAN ZHANG2, EVAN T. KELLER3 and MIKIO NAMIKI1 1Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan; 2Center for Translational Medical Research, Guangxi Medical University, Guangxi, P.R. China; 3Department of Urology, School of Medicine, University of Michigan, Ann Arbor, MI, U.S.A. Abstract. Background: Prevention of the development of line hormonal therapy using medical castration, such as castration-resistant from hormone-naïve prostate cancer is luteinizing hormone releasing hormone (LH-RH) agonists, an important issue in maintaining the quality of life of the LH-RH antagonist, and antiandrogen for advanced PCa. patients. We explored the effect of 2’-hydroxyflavanone on After an initial response to ADT, however, PCa eventually proliferation and androgen responsiveness using prostate loses responsiveness to ADT and progresses into what is cancer cell lines. Materials and Methods: To investigate the termed castration-resistant PCa (CRPC). effect of 2’-hydroxyflavanone on proliferation, prostate The AR axis also plays an important part in the process cancer cells were treated with 2’-hydroxyflavanone. when hormone- sensitive PCa become CRPC. Although Androgen-responsiveness in LNCaP cells was confirmed by serum testosterone decreases to less than 5% before starting luciferase assay after transfection of luciferase reporter ADT, PCa adapts to low serum testosterone level by several driven by prostate specific antigen promoter. To detect mechanisms.
    [Show full text]
  • Osteoblast-Derived Factors Induce Androgen-Independent Proliferation and Expression of Prostate-Specific Antigen in Human Prostate Cancer Cells
    1860 Vol. 10, 1860–1869, March 1, 2004 Clinical Cancer Research Osteoblast-Derived Factors Induce Androgen-Independent Proliferation and Expression of Prostate-Specific Antigen in Human Prostate Cancer Cells Natalie Blaszczyk,1 Bassam A. Masri,4 cotreated with both OCM and androgen. OCM targeted the 1 1 Nasrin R. Mawji, Takeshi Ueda, NH2-terminal domain of the AR. The effect of OCM on transcriptional activity of the AR was inhibited by an anti- Gavan McAlinden,4 Clive P. Duncan,4 1 2 androgen. Neutralizing antibodies to IL-6 blocked prolifer- Nicholas Bruchovsky, Hans-Udo Schweikert, ation and expression of PSA by OCM. 2 3 Doris Schnabel, Edward C. Jones, and Conclusion: Osteoblasts secrete factors, such as IL-6, Marianne D. Sadar1 that cause androgen-independent induction of PSA gene 1Department of Cancer Endocrinology, British Columbia Cancer expression and proliferation of prostate cancer cells by a Agency, Vancouver, British Columbia, Canada; 2Department of mechanism that partially relies on the AR. Identifying such Internal Medicine, University of Bonn, Bonn, Germany; and molecular mechanisms may lead to improved clinical man- 3 4 Anatomical Pathology and Orthopaedic Surgery, Vancouver agement of metastatic prostate cancer. General Hospital, British Columbia, Canada INTRODUCTION ABSTRACT Localized carcinoma of the prostate (CaP) can potentially Purpose: Prostate cancer metastasizes to the skeleton to be cured by surgery or radiation therapy. However, the only form osteoblastic lesions. Androgen ablation is the current treatment available for advanced metastatic disease is the with- treatment for metastatic prostate cancer. This therapy drawal of androgens, which are essential for the survival of is palliative, and the disease will return in an androgen- prostate epithelial cells (for review, see Ref.
    [Show full text]
  • Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of B(1,6)-Branched Oligosaccharides As a Marker of Tumor Progression
    Published OnlineFirst January 18, 2012; DOI: 10.1158/1078-0432.CCR-11-2900 Clinical Cancer Imaging, Diagnosis, Prognosis Research Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of b(1,6)-Branched Oligosaccharides as a Marker of Tumor Progression Tobias Lange1, Sebastian Ullrich1, Imke Muller€ 1, Michael F. Nentwich1,2, Katrin Stubke€ 1, Susanne Feldhaus1, Christine Knies1, Olaf J.C. Hellwinkel3, Robert L. Vessella7, Claudia Abramjuk8, Mario Anders4, Jennifer Schroder-Schwarz€ 4, Thorsten Schlomm3,6, Hartwig Huland6, Guido Sauter5, and Udo Schumacher1 Abstract Purpose: To establish xenograft mouse models of metastatic and nonmetastatic human prostate cancer and to apply these models to the search for aberrant glycosylation patterns associated with tumor progression in vivo and in patients. Experimental Design: Prostate cancer cells (LNCaP, PC-3, LuCaP 23.1, and DU-145) were xeno- À À À À grafted subcutaneously into immunodeficient pfp / /rag2 / mice. Tumor growth and metastasis formation were quantified and as altered glycosylation patterns have been associated with metastasis formation in several other malignancies, prostate cancer cells were profiled by a quantitative real-time PCR (qRT-PCR) glycosylation array and compared with normal human prostate cells. The activity of upregulated glycosyltransferases was analyzed by their sugar residues end products using lectin histochemistry on primary tumors and metastases in the animal experiments and on 2,085 clinical samples. Results: PC-3 cells produced the largest number of spontaneous lung metastases, followed by LNCaP and LuCaP 23.1, whereas DU-145 was nonmetastatic. qRT-PCR revealed an upregulation of b1,6-N- acetylglucosaminyltransferase-5b (Mgat5b) in all prostate cancer cell lines.
    [Show full text]
  • Androgen Receptor As a Licensing Factor for DNA Replication in Androgen-Sensitive Prostate Cancer Cells
    Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells Ivan V. Litvinov*†, Donald J. Vander Griend*‡, Lizamma Antony*, Susan Dalrymple*, Angelo M. De Marzo‡§, Charles G. Drake‡¶, and John T. Isaacs*†‡ʈ *Chemical Therapeutics Program, ¶Division of Immunology and Hematopoiesis, The Sidney Kimmel Comprehensive Cancer Center, †Cellular and Molecular Medicine Graduate Program, §Department of Pathology, and the ‡Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231 Edited by Owen N. Witte, University of California, Los Angeles, CA, and approved August 11, 2006 (received for review April 16, 2006) Androgen receptor (AR) protein expression and function are critical AR-stimulated growth (11). As part of this malignant conversion, for survival and proliferation of androgen-sensitive (AS) prostate AR undergoes a molecular switch from its ability to suppress cancer cells. Besides its ability to function as a transcription factor, proliferation of normal prostatic epithelia to directly stimulating the experimental observations suggest that AR becomes a licensing proliferation of prostate cancer cells (4, 11, 12). Such a molecular factor for DNA replication in AS prostate cancer cells and thus must switch requires gain-of-function changes in AR signaling. Recent be degraded during each cell cycle in these cells to allow reinitia- studies documented that one such gain-of-function event involves tion of DNA replication in the next cell cycle. This possibility was DNA rearrangement such that the androgen response element is tested by using the AS human prostate cancer cell lines, LNCaP, translocated to confer androgen responsiveness upon promoters for CWR22Rv1, and LAPC-4.
    [Show full text]